Jennifer Barrett

Data from 2 studies evaluating guselkumab (Tremfya, Janssen) in active psoriatic arthritis were presented at the American College of Rheumatology and Association of Rheumatology Professionals 2019 Annual Meeting.

Immunotherapy drug blinatumomab showed benefit in pediatric patients with relapsed acute lymphoblastic leukemia who have minimal residual disease following chemotherapy.

In a session at the American Society of Hematology Annual Meeting and Exposition, held December 7-10 in Orlando, Florida, experts presented on the evolution of CLL therapy, how to make treatment decisions, and what’s to come in the future based on ongoing studies.

The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.

A novel, off-the-shelf bispecific antibody could serve as a new treatment option for patients with non-Hodgkin lymphoma who don’t respond to CAR T-cell therapy.

A study looked at adherence rates and potential predictors of nonadherence in patients with hemophilia receiving emicizumab.

The analysis evaluated emerging mutations in patients with relapsed/refractory acute myeloid leukemia receiving gilteritinib therapy in the phase 3 ADMIRAL study.

Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies.

Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers (PBMs), and manufacturers to reduce drug spend.

Officials with the FDA have approved fingolimod (Gilenya, Novartis) for the treatment of relapsing multiple sclerosis (MS) in pediatric patients aged 10 years and older.

Nivolumab plus low-dose ipilimumab combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced renal cell carcinoma.

It is well known that competition can help lower prices of generic drugs, but just how much is needed to effectively reduce costs?

Migraines may be an important risk factor for several cardiovascular diseases, apart from stroke and heart attacks.

In newly-released scientific analysis and data, the FDA has indicated strong evidence of the presence of compounds in kratom that strongly bind to opioid receptors, according to a statement released by FDA Commissioner Scott Gottlieb, MD.

This year’s flu season is on track to exceed previous seasons of high severity in hospitalization rates as influenza activity and related deaths continue to climb across the United States, according to a CDC media briefing held today.

FDA officials have released guidance on the development of generic abuse-deterrent opioids.

US News & World Report recently released its ranking of the highest paying and best overall jobs of 2018, and pharmacists made the cut for both lists.

This year’s influenza season has reached epidemic levels, according to a recent CDC briefing on current US flu activity.

To ensure the safe infusion of high-alert medications, titrations need to be protected from harmful dosing changes, according to a poster presentation at the 2017 ASHP Midyear Clinical Meeting and Exhibition.

The cost savings for a generic version of an orally administered cancer treatment was less than expected.

In the case of DIR fees, which are the top concern of independent community pharmacies, NCPA's comments push for enactment of S. 413 / H.R. 1038.

Pharmacists see adults aged 50 years and older about 4 times more than physicians do, which opens opportunities for counseling and recommendations about vaccination.

The film provides several takeaways for pharmacists, who have taken on an increasingly active role in vaccines, especially in influenza vaccination.

When palliative care is involved, they address the physical, as well as psychosocial symptoms, to improve quality of life.

The new warning is based on recent data from 2 clinical trials.

The new bill would ideally spur competition in market areas where it does not normally exist.

Generic sterile injectable drugs are especially susceptible to shortage because of their short shelf life.

The indictments contain a combined 477 charges that include counts of money laundering, health care fraud, and unlawfully selling prescriptions of controlled substances.

Two new fixed-dose basal/GLP-1 receptor-agonist agents, Soliqua 100/33 (Sanofi) and Xultophy 100/3.6 (Novo Nordisk), were approved by the FDA in November 2016.